Last updated on June 2020

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Brief description of study

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Detailed Study Description

This study has several treatment arms and each treatment arm has 2 stages. During Stage 1 - AB928 plus zimberelimab alone, AB928 plus zimberelimab with or without a standard of care treatment (enzalutamide or docetaxel), or AB928 plus AB680 with or without zimberelimab will be administered to participants with mCRPC.

During Stage 2 - Additional participants with mCRPC may receive an AB928-based combination therapy evaluated in Stage 1 or, a standard of care treatment.

A pharmacokinetic (PK) Sub-Study (AB928 plus zimberelimab) will be conducted separately.

Treatment may continue until unacceptable toxicity or progressive disease, or other reasons specified in the protocol.

Clinical Study Identifier: NCT04381832

Find a site near you

Start Over

San Francisco, CA

San Francisco, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.